MeSH tree: D12.776.377.715.548.114.224.200.829
Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine ...
Feb 17, 2025
0
63
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Jan 28, 2025
0
45
Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease. Despite advances in treatment, survival rates for high-risk and ...
Jan 23, 2025
0
13
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.
Jan 3, 2025
0
28
A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation factor 15 (GDF-15) can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors.
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center ...
Nov 14, 2024
0
17
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical ...
Nov 1, 2024
0
39
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal ...
Oct 16, 2024
1
75
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for Immunotherapy, and Bristol Myers Squibb has published the most comprehensive overview to date of ...
Oct 1, 2024
0
71
The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The phase II portion of the NRG-HN005 evaluated two experimental treatment ...
Sep 30, 2024
0
25
